STOCK TITAN

Aurinia Pharmaceuticals Inc - AUPH STOCK NEWS

Welcome to our dedicated news page for Aurinia Pharmaceuticals (Ticker: AUPH), a resource for investors and traders seeking the latest updates and insights on Aurinia Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aurinia Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aurinia Pharmaceuticals's position in the market.

Rhea-AI Summary
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will attend the 2024 Bloom Burton & Co. Healthcare Investor Conference in Toronto, hosting one-on-one meetings with investors and a presentation on April 16. The event will be webcasted on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none
-
Rhea-AI Summary
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will release its first quarter financial and operational results on May 2, 2024. The management team will host a conference call/webcast to review the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
-
Rhea-AI Summary
Aurinia Pharmaceuticals Inc. (AUPH) will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference in Toronto. Management will engage with investors in one-on-one meetings, fireside chat, and Q&A session on April 16, 2024. A live webcast will be accessible on Aurinia's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
none
Rhea-AI Summary
Aurinia Pharmaceuticals Inc. receives exemptive relief for a share repurchase program, allowing the purchase of up to 15% of its shares over 36 months. The Board approved a $150 million Current Program, showcasing confidence in the Company's growth prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
buyback
-
Rhea-AI Summary
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announces participation in upcoming investor conferences in March 2024, including TD Cowen’s 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference. Management will engage in one-on-one meetings, fireside chats, and Q&A sessions to discuss the company's progress and future plans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
conferences
-
Rhea-AI Summary
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) reported strong financial performance with total net revenue of $45.1 million for the fourth quarter and $175.5 million for the full year 2023. Net product revenue showed significant growth, reaching $42.3 million for the quarter and $158.5 million for the year. The company reaffirmed its 2024 net product revenue guidance of $200 - $220 million. Operational changes are expected to drive savings of $50 - $55 million annually, with a share repurchase program of up to $150 million initiated. Aurinia will discontinue future development of AUR200 and AUR300 programs to focus on commercial execution of LUPKYNIS. The Board approved the share repurchase program to enhance shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.47%
Tags
Rhea-AI Summary
Aurinia Pharmaceuticals Inc. (AUPH) is set to release its 2023 fourth quarter and full year financial and operational results on February 15, 2024. The management team will host a conference call/webcast to review the results and provide a general business update. Interested participants can access the webcast through the company's corporate website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
-
Rhea-AI Summary
Life Sciences Ontario announces the recipients of its 2024 LSO Awards, recognizing outstanding individuals and companies in the life sciences sector. The awardees include Bill Mantel, Dr. Benjamin Rovinski, Dr. Christine Allen, Dr. Durhane Wong-Rieger, and Satellos Bioscience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Aurinia Pharmaceuticals Inc. (AUPH) reported preliminary unaudited net product revenue of $42 million for Q4 2023, representing 49% growth from the same period in 2022. Full-year net product revenue was approximately $159 million, showing a 53% increase. Total unaudited net revenue for Q4 2023 was $45 million, a 59% growth from the same period in 2022, and $176 million for the full year, a 31% increase. The company had approximately $351 million in cash, cash equivalents, restricted cash, and investments as of December 31, 2023. The net product revenue guidance for 2024 is in the range of $200-$220 million, with a target to become cash flow positive in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
none
Rhea-AI Summary
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has submitted its Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for AUR200, a potent recombinant fusion protein with a high affinity for targeting both BAFF and APRIL. AUR200 will be studied in a Phase 1 first-in-human trial in healthy volunteers, marking a significant advancement for Aurinia’s emerging autoimmune pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.11%
Tags
Aurinia Pharmaceuticals Inc

Nasdaq:AUPH

AUPH Rankings

AUPH Stock Data

723.09M
131.74M
7.45%
38.61%
8.47%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Victoria

About AUPH

aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, canada.